River blindness: reducing the risk in at-risk populations

References

• African Programme for Onchocerciasis Control – report of the sixth meeting of national task forces, October 2009. Wkly Epidemiol. Rec.85(4), 23–28 (2009).
   Google Scholar
• Richards FO Jr, Miri ES, Katabarwa M et al. The Carter Center’s assistance to river blindness control programs: establishing treatment objectives and goals for monitoring ivermectin delivery systems on two continents. Am. J. Trop. Med. Hyg.65(2), 108–114 (2001).
   PubMed Web of Science ®Google Scholar
• Udall DN. Recent updates on onchocerciasis: diagnosis and treatment. Clin. Infect. Dis.44(1), 53–60 (2007).
   PubMed Web of Science ®Google Scholar
• Boatin BA, Richards FO Jr. Control of onchocerciasis. Adv. Parasitol.61, 349–394 (2006).
   PubMed Web of Science ®Google Scholar
• Foster A, Gilbert C, Johnson G. Changing patterns in global blindness: 1988–2008. Comm. Eye Health21(67), 37–39 (2008).
   PubMedGoogle Scholar
• Oye JE, Kuper H. Prevalence and causes of blindness and visual impairment in Limbe urban area, South West Province, Cameroon. Br. J. Ophthalmol.91(11), 1435–1439 (2007).
   PubMed Web of Science ®Google Scholar
• Pizzarello L, Abiose A, Ffytche T et al. VISION 2020: the right to sight: a global initiative to eliminate avoidable blindness. Arch. Ophthalmol.122(4), 615–620 (2004).
   PubMed Web of Science ®Google Scholar
• Amazigo U. The African Programme for Onchocerciasis Control (APOC). Ann. Trop. Med. Parasitol.102(Suppl. 1), 19–22 (2008).
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Pilkington EF, Dance D, Sauerbrey M, Richards FO. River blindness: old disease, new challenges. Ophthal. Int.53–56 (2008).
   Google Scholar
• Hall LR, Pearlman E. Pathogenesis of Onchocercal keratitis (river blindness). Clin. Microbiol. Rev.12(3), 445–453 (1999).
   PubMed Web of Science ®Google Scholar
• Tonjum AM, Thylefors B. Aspects of corneal changes in onchocerciasis. Br. J. Ophthalmol.62(7), 458–461 (1978).
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Proano R, Oliva O et al. The reliability of anterior segment lesions as indicators of onchocercal eye disease in Guatemala. Am. J. Trop. Med. Hyg.75(6), 1058–1062 (2006).
   PubMedGoogle Scholar
• Abiose A. Onchocercal eye disease and the impact of Mectizan treatment. Ann. Trop. Med. Parasitol.92(Suppl. 1), S11–S22 (1998).
   Web of Science ®Google Scholar
• Saint Andre A, Blackwell NM, Hall LR et al. The role of endosymbiotic Wolbachia bacteria in the pathogenesis of river blindness. Science295(5561), 1892–1895 (2002).
   Google Scholar
• Pearlman E. Immunopathogenesis of Onchocerca volvulus keratitis (river blindness): a novel role for endosymbiotic Wolbachia bacteria. Med. Microbiol. Immunol.192(1), 57–60 (2003).
   PubMedGoogle Scholar
• Hoerauf A, Volkmann L, Hamelmann C et al. Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis. Lancet355(9211), 1242–1243 (2000).
   PubMed Web of Science ®Google Scholar
• Keiser PB, Reynolds SM, Awadzi K, Ottesen EA, Taylor MJ, Nutman TB. Bacterial endosymbionts of Onchocerca volvulus in the pathogenesis of posttreatment reactions. J. Infect. Dis.185(6), 805–811 (2002).
   PubMed Web of Science ®Google Scholar
• Brattig NW, Rathjens U, Ernst M, Geisinger F, Renz A, Tischendorf FW. Lipopolysaccharide-like molecules derived from Wolbachia endobacteria of the filaria Onchocerca volvulus are candidate mediators in the sequence of inflammatory and antiinflammatory responses of human monocytes. Microbes Infect.2(10), 1147–1157 (2000).
   PubMedGoogle Scholar
• Yang YF, Cousens S, Murdoch IE, Babalola OE, Abiose A, Jones B. Intraocular pressure and gonioscopic findings in rural communities mesoendemic and nonendemic for onchoceriasis, Kaduna State, Nigeria. Eye (Lond.)15(Pt 6), 756–759 (2001).
   PubMedGoogle Scholar
• Stilma JS. Onchocerciasis and glaucoma: ophthalmo–pathological aspects of the limbus and Tenon’s capsule in 25 surgical patients from Ghana. Doc. Ophthalmol.50(2), 327–335 (1981).
   PubMedGoogle Scholar
• Egbert PR, Jacobson DW, Fiadoyor S, Dadzie P, Ellingson KD. Onchocerciasis: a potential risk factor for glaucoma. Br. J. Ophthalmol.89(7), 796–798 (2005).
   PubMedGoogle Scholar
• Cooper PJ, Guderian RH, Proano R, Taylor DW. The pathogenesis of chorioretinal disease in onchocerciasis. Parasitol. Today13(3), 94–98 (1997).
   PubMedGoogle Scholar
• Semba RD, Murphy RP, Newland HS, Awadzi K, Greene BM, Taylor HR. Longitudinal study of lesions of the posterior segment in onchocerciasis. Ophthalmology97(10), 1334–1341 (1990).
   PubMed Web of Science ®Google Scholar
• Murdoch I, Abiose A, Babalola O et al. Ivermectin and Onchocercal optic neuritis: short-term effects. Eye (Lond.)8(Pt 4), 456–461 (1994).
   PubMed Web of Science ®Google Scholar
• Newland HS, White AT, Greene BM, Murphy RP, Taylor HR. Ocular manifestations of onchocerciasis in a rain forest area of west Africa. Br. J. Ophthalmol.75(3), 163–169 (1991).
   PubMed Web of Science ®Google Scholar
• Vincent JA, Lustigman S, Zhang S, Weil GJ. A comparison of newer tests for the diagnosis of onchocerciasis. Ann. Trop. Med. Parasitol.94(3), 253–258 (2000).
   PubMed Web of Science ®Google Scholar
• Ayong LS, Tume CB, Wembe FE et al. Development and evaluation of an antigen detection dipstick assay for the diagnosis of human onchocerciasis. Trop. Med. Int. Health10(3), 228–233 (2005).
   PubMedGoogle Scholar
• Awadzi K, Gilles HM. Diethylcarbamazine in the treatment of patients with onchocerciasis. Br. J. Clin. Pharmacol.34(4), 281–288 (1992).
   PubMedGoogle Scholar
• Thylefors B. The Mectizan Donation Program (MDP). Ann. Trop. Med. Parasitol.102(Suppl. 1), 39–44 (2008).
   PubMed Web of Science ®Google Scholar
• Taylor MJ, Awadzi K, Basanez MG et al. Onchocerciasis control: vision for the future from a Ghanian perspective. Parasit. Vectors2(1), 7 (2009).
   PubMed Web of Science ®Google Scholar
• Mabey D, Whitworth JA, Eckstein M, Gilbert C, Maude G, Downham M. The effects of multiple doses of ivermectin on ocular onchocerciasis. A six-year follow-up. Ophthalmology103(7), 1001–1008 (1996).
   PubMed Web of Science ®Google Scholar
• Chippaux JP, Boussinesq M, Fobi G et al. Effect of repeated ivermectin treatments on ocular onchocerciasis: evaluation after six to eight doses. Ophthalmic Epidemiol.6(4), 229–246 (1999).
   PubMedGoogle Scholar
• Diawara L, Traore MO, Badji A et al. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS Negl. Trop. Dis.3(7), e497 (2009).
   PubMed Web of Science ®Google Scholar
• Gardon J, Gardon-Wendel N, Demanga N, Kamgno J, Chippaux JP, Boussinesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet350(9070), 18–22 (1997).
   PubMed Web of Science ®Google Scholar
• Boussinesq M, Gardon J, Gardon-Wendel N, Chippaux JP. Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon. Filaria J.2(Suppl. 1), S4 (2003).
   PubMedGoogle Scholar
• Hoerauf A, Specht S, Marfo-Debrekyei Y et al. Efficacy of 5-week doxycycline treatment on adult Onchocerca volvulus.Parasitol. Res.104(2), 437–447 (2009).
   PubMedGoogle Scholar
• Specht S, Hoerauf A, Adjei O, Debrah A, Buttner DW. Newly acquired Onchocerca volvulus filariae after doxycycline treatment. Parasitol. Res.106(1), 23–31 (2009).
   PubMedGoogle Scholar
• Hoerauf A, Specht S, Buttner M et al. Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study. Med. Microbiol. Immunol.197(3), 295–311 (2008).
   PubMed Web of Science ®Google Scholar
• Hoerauf A, Mand S, Volkmann L et al. Doxycycline in the treatment of human onchocerciasis: kinetics of Wolbachia endobacteria reduction and of inhibition of embryogenesis in female Onchocerca worms. Microbes Infect.5(4), 261–273 (2003).
   PubMed Web of Science ®Google Scholar
• Specht S, Mand S, Marfo-Debrekyei Y et al. Efficacy of 2- and 4-week rifampicin treatment on the Wolbachia of Onchocerca volvulus.Parasitol. Res.103(6), 1303–1309 (2008).
   PubMed Web of Science ®Google Scholar
• Richards FO Jr, Amann J, Arana B et al. No depletion of Wolbachia from Onchocerca volvulus after a short course of rifampin and/or azithromycin. Am. J. Trop. Med. Hyg.77(5), 878–882 (2007).
   PubMed Web of Science ®Google Scholar
• Hoerauf A, Marfo-Debrekyei Y, Buttner M et al. Effects of 6-week azithromycin treatment on the Wolbachia endobacteria of Onchocerca volvulus.Parasitol. Res.103(2), 279–286 (2008).
   PubMed Web of Science ®Google Scholar
• Remme JHF, Feenstra P, Lever PR et al. Tropical diseases targeted for elimination: Chagas disease, lymphatic filariasis, onchocerciasis, and leprosy. In: Disease Control Priorities in Developing Countries. Jamison DT (Ed.). Oxford University Press, NY, USA, 433–449 (2006).
   Google Scholar
• Katabarwa MN, Eyamba A, Chouaibou M et al. Does onchocerciasis transmission take place in hypoendemic areas? A study from the North Region of Cameroon. Trop. Med. Int. Health15(5), 645–652 (2010).
   PubMed Web of Science ®Google Scholar
• Cousens SN, Cassels-Brown A, Murdoch I et al. Impact of annual dosing with ivermectin on progression of Onchocercal visual field loss. Bull. World Health Organ.75(3), 229–236 (1997).
   PubMed Web of Science ®Google Scholar
• Emukah EC, Osuoha E, Miri ES et al. A longitudinal study of impact of repeated mass ivermectin treatment on clinical manifestations of onchocerciasis in Imo State, Nigeria. Am. J. Trop. Med. Hyg.70(5), 556–561 (2004).
   PubMed Web of Science ®Google Scholar
• Anosike JC, Dozie IN, Ameh GI et al. The varied beneficial effects of ivermectin (Mectizan) treatment, as observed within onchocerciasis foci in south-eastern Nigeria. Ann. Trop. Med. Parasitol.101(7), 593–600 (2007).
   PubMed Web of Science ®Google Scholar
• Kennedy MH, Bertocchi I, Hopkins AD, Meredith SE. The effect of 5 years of annual treatment with ivermectin (Mectizan) on the prevalence and morbidity of onchocerciasis in the village of Gami in the Central African Republic. Ann. Trop. Med. Parasitol.96(3), 297–307 (2002).
   PubMed Web of Science ®Google Scholar
• Little MP, Basanez MG, Breitling LP, Boatin BA, Alley ES. Incidence of blindness during the onchocerciasis control programme in western Africa, 1971–2002. J. Infect. Dis.189(10), 1932–1941 (2004).
   PubMed Web of Science ®Google Scholar
• Newland HS, White AT, Greene BM et al. Effect of single-dose ivermectin therapy on human Onchocerca volvulus infection with Onchocercal ocular involvement. Br. J. Ophthalmol.72(8), 561–569 (1988).
   PubMed Web of Science ®Google Scholar
• Dadzie KY, Remme J, Alley ES, de Sole G. Changes in ocular onchocerciasis four and twelve months after community-based treatment with ivermectin in a holoendemic onchocerciasis focus. Trans. R. Soc. Trop. Med. Hyg.84(1), 103–108 (1990).
   PubMed Web of Science ®Google Scholar
• Dadzie KY, Remme J, de Sole G. Changes in ocular onchocerciasis after two rounds of community-based ivermectin treatment in a holo-endemic onchocerciasis focus. Trans. R. Soc. Trop. Med. Hyg.85(2), 267–271 (1991).
   PubMed Web of Science ®Google Scholar
• Taylor HR, Semba RD, Newland HS et al. Ivermectin treatment of patients with severe ocular onchocerciasis. Am. J. Trop. Med. Hyg.40(5), 494–500 (1989).
   PubMedGoogle Scholar
• Waters HR, Rehwinkel JA, Burnham G. Economic evaluation of Mectizan distribution. Trop. Med. Int. Health9(4), A16–A25 (2004).
   PubMed Web of Science ®Google Scholar
• No authors listed. Report from the 2009 Inter-American Conference on Onchocerciasis: progress towards eliminating river blindness in the Region of the Americas. Wkly Epidemiol. Rec.85(33), 321–326 (2010).
   PubMedGoogle Scholar
• Zimmerman PA, Katholi CR, Wooten MC, Lang-Unnasch N, Unnasch TR. Recent evolutionary history of American Onchocerca volvulus, based on analysis of a tandemly repeated DNA sequence family. Mol. Biol. Evol.11(3), 384–392 (1994).
   PubMed Web of Science ®Google Scholar
• Vieira JC, Cooper PJ, Lovato R et al. Impact of long-term treatment of onchocerciasis with ivermectin in Ecuador: potential for elimination of infection. BMC Med.5, 9 (2007).
   PubMedGoogle Scholar
• Neto GH, Jaegger K, Marchon-Silva V et al. Eye disease related to onchocerciasis: a clinical study in the Aratha-u, Yanomami Tribe, Roraima State, Brazil. Acta Trop.112(2), 115–119 (2009).
   PubMedGoogle Scholar
• Duerr HP, Raddatz G, Eichner M. Diagnostic value of nodule palpation in onchocerciasis. Trans. R. Soc. Trop. Med. Hyg.102(2), 148–154 (2008).
   PubMedGoogle Scholar